ARIA
Library/anti aging/P21 / Cerebrolysin Active Peptide

P21 / Cerebrolysin Active Peptide

Not FDA Approved✓ WADA Permitted

Cerebrolysin Mimetic

anti agingExperimentalNeuroprotective Peptide Fragment

Synthetic peptide fragment mimicking Cerebrolysin active site. Promotes neuronal survival, synaptic plasticity, and cognitive function with defined molecular structure.

Confidence
40%
Half-Life 6-8 hours
Cost ~$120/mo
Quick Reference
RouteIntranasal or SC injection
MechanismMimics NGF/BDNF signaling. Activates TrkA/TrkB. Enhances synaptic plasticity via...
Mol. Weight1200 Da
Reviewed2026-07-15

Mechanism of Action

Mimics NGF/BDNF signaling. Activates TrkA/TrkB. Enhances synaptic plasticity via CREB. Reduces amyloid-beta toxicity. Stimulates hippocampal neurogenesis.

Dosing Protocol

Intranasal: 10-20 mg daily. SC: 5-10 mg daily. 4 weeks on, 2 off.

Key Studies

2012

P21 neuroprotective properties

PMID 23146452preclinical
2018

Intranasal neurotrophic peptides

PMID 30156789review

Adverse Effects

Contraindications

    Storage

    2-8°C. Protect from light. Use within 14 days.

    Clinical Applications

    • Cognitive decline prevention
    • post-concussion recovery
    • age-related memory loss